HOME ·

HBM HOLDINGS-B

HBM HOLDINGS-B (02142.HK): Partner Solstice Oncology Closes USD 225 Million Series A Financing
Tags：
HBM HOLDINGS-B02142.HKR&D Progressfinancing
2026-09-09
HBM HOLDINGS-B (02142.HK): Positive Phase II Interim Results for HBM9378/WIN378 in Asthma; Phase III Initiated
Tags：
HBM HOLDINGS-B02142.HKR&D Progress
2026-09-08
HBM HOLDINGS-B (02142.HK): Shares Added to Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Lists, Effective 7 September 2026
Tags：
HBM HOLDINGS-B02142.HK
2026-09-07
HBM HOLDINGS-B (02142.HK): IND application of HBM7004 for advanced solid tumors approved by NMPA
Tags：
HBM HOLDINGS-B02142.HKClinical Trial
2026-08-18
HBM HOLDINGS-B (02142.HK): Expected Profit of USD62 Million–USD67 Million for H1 2026; Revenue Stood at Approximately USD101 Million in Corresponding Period Last Year
Tags：
HBM HOLDINGS-B02142.HKpositive profit alert
2026-07-24
HBM HOLDINGS-B (02142.HK): NMPA Accepts IND Application of HBM7004 for Advanced Solid Tumors
Tags：
HBM HOLDINGS-B02142.HKClinical Trial
2026-06-10
HBM HOLDINGS-B (02142.HK): Preclinical Data Unveiled for First AI-Derived Candidate LET003, Showing Remarkable Fat Loss & Muscle Preservation Combined with Semaglutide
Tags：
HBM HOLDINGS-B02142.HKpreclinical data
2026-05-18
HBM HOLDINGS-B(02142.HK): Independent Non-executive Director Ye Xiaoping Under CSRC Case Investigation
Tags：
HBM HOLDINGS-B02142.HKcase filing notice
2026-05-13
HBM HOLDINGS-B(02142.HK) will spend HKD 10.27 million to repurchase 800 thousand shares on May 6, 2026
Tags：
HBM HOLDINGS-B02142.HK
2026-05-06
HBM HOLDINGS-B (02142.HK): Bispecific Antibody HBM7575 Approved for Clinical Trial by NMPA
Tags：
HBM HOLDINGS-B02142.HKinvestigational new drug
2026-03-09